Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Research programme: melanocortin receptor modulators - Palatin Technologies

Drug Profile

Research programme: melanocortin receptor modulators - Palatin Technologies

Alternative Names: PL-8331; PL-8905; PT 18

Latest Information Update: 15 May 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Palatin Technologies
  • Class Anti-inflammatories; Antihyperglycaemics; Eye disorder therapies; Obesity therapies; Peptides; Skin disorder therapies; Small molecules
  • Mechanism of Action Melanocortin receptor agonists; Melanocortin type 1 receptor agonists; Melanocortin type 3 receptor agonists; Melanocortin type 4 receptor agonists; Melanocortin type 4 receptor antagonists; Melanocortin type 5 receptor agonists; Melanocortin type 5 receptor modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Preclinical Diabetes mellitus; Dry eyes; Inflammatory bowel diseases; Obesity
  • No development reported Cachexia; Erythropoietic protoporphyria; Inflammation; Kidney disorders; Nephritis; Uveitis; Vitiligo

Most Recent Events

  • 09 May 2018 Preclinical development in Dry-eyes is ongoing in USA
  • 03 Jan 2018 Palatin Technologies plans a phase I trial for Ulcerative colitis in USA (Subcutaneous) in the first quarter of 2018
  • 04 Nov 2017 No recent reports of development identified for preclinical development in Cachexia in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top